IRAG1-AS1: A Promising Drug Target / Biomarker (G100129827)

Target Name: IRAG1-AS1

NCBI ID: G100129827

IRAG1-AS1

Other Name(s): IRAG1 antisense RNA 1 | IRAG1 antisense RNA 1, transcript variant 1 | MRVI1 antisense RNA 1 (non-protein coding) | MRVI1-AS1

IRAG1-AS1: A Promising Drug Target / Biomarker

The interleukin-1伪 (IL-1伪) gene is a key regulator of inflammation and immune responses in humans. It is involved in the regulation of various cellular processes that are crucial for the immune system's response to infection and injury. One of the functions of IL-1伪 is to induce the production of pro-inflammatory cytokines, which play a central role in the inflammatory response. However, excessive or uncontrolled production of these cytokines can lead to a range of diseases, including autoimmune disorders, chronic pain, and even cancer.

One of the most promising drug targets for IL-1伪 is the G protein-coupled receptor (GPCR) IRAG1-AS1. This protein is known to be a key regulator of IL-1伪 signaling and has been shown to play a role in the regulation of various cellular processes, including inflammation, pain, and survival.

The Structure and Function of IRAG1-AS1

IRAG1-AS1 is a 21-kDa protein that is expressed in various tissues and cells, including macrophages, dendritic cells, and cancer cells. It is a GPCR that is characterized by a long extracellular domain, a transmembrane segment, and an intracellular domain. The intracellular domain is known to be involved in the regulation of IL-1伪 signaling and is thought to play a key role in the regulation of inflammation and immune responses.

The IRAG1-AS1 receptor is composed of two transmembrane domains, which are involved in the regulation of ion channels and the formation of ionic bonds with other molecules. The first transmembrane domain is known as the N-terminus and is responsible for the regulation of ion channels. This domain has been shown to be involved in the regulation of various cellular processes, including the regulation of ion channels, the production of reactive oxygen species (ROS), and the regulation of cell adhesion.

The second transmembrane domain is known as the C-terminus and is responsible for the regulation of ion channels and the formation of ionic bonds with other molecules. This domain has been shown to be involved in the regulation of various cellular processes, including the regulation of ion channels, the production of ROS, and the regulation of cell adhesion.

The IRAG1-AS1 Receptor Signaling Pathway

The IRAG1-AS1 receptor is involved in the regulation of various cellular processes, including the regulation of inflammation and immune responses. This is accomplished through the regulation of various intracellular signaling pathways, including the T cell signaling pathway and the NF-kappa-B signaling pathway.

The T cell signaling pathway is involved in the regulation of cellular immunity and is thought to play a key role in the regulation of IRAG1-AS1 signaling. This pathway is characterized by the production of various cytokines, including T cell-derived cytokines (TDCs) and natural killer (NK) cytokines. TDCs are thought to play a key role in the regulation of IRAG1-AS1 signaling and have been shown to play a role in the regulation of various cellular processes, including the regulation of inflammation and immune responses.

The NF-kappa-B signaling pathway is a central regulator of inflammation and immune responses. It is composed of various nuclear factor kappa B (NFKB) transcription factors, including IRAK4 and IRAK1. These transcription factors are involved in the regulation of various cellular processes, including the production of pro-inflammatory cytokines. The NF-kappa-B signaling pathway is thought to play

Protein Name: IRAG1 Antisense RNA 1

The "IRAG1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IRAG1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets